stockrowPharvaris N.V.
PHVS Healthcare Biotechnology
- EPS
- +13.8%
- Free cash flow
- −17.3%
- Total debt
- +4.31%
Quarter to June 2026, against a year earlier
Follow PHVS
Alert me
Pharvaris N.V. (PHVS) Free cash flow
Pharvaris N.V.'s free cash flow for fiscal 2025 was −$155.3M, compared with −$130.6M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$178.1M. Over the past ten years it has ranged from −$155.3M (fiscal 2025) to −$4.6M (fiscal 2018) — the current reading is the lowest in ten years. Free cash flow has fallen for 7 consecutive fiscal years. Pharvaris N.V. ranks 529th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$155.3M | — |
| FY2024 | −$130.6M | — |
| FY2023 | −$100.8M | — |
| FY2022 | −$70.9M | — |
| FY2021 | −$52.9M | — |
| FY2020 | −$24.6M | — |
| FY2019 | −$7.5M | — |
| FY2018 | −$4.6M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | −$43.6M | — |
| Mar 2026 | −$57.1M | — |
| Dec 2025 | −$39.2M | — |
| Sep 2025 | −$38.2M | — |
| 19 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ADMA ADMA Biologics Inc compare | $140.5M |
| VCEL Vericel Corporation compare | $57.9M |
| PVLA Palvella Therapeutics, Inc. compare | −$36.5M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$150.9M |
| PHVS Pharvaris N.V. | −$178.1M |
| IMNM Immunome, Inc. compare | −$219.1M |
| CLDX Celldex Therapeutics, Inc. compare | −$242.1M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$314.5M |
| BHVN Biohaven Ltd. compare | −$473.2M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)